📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Scienture

1.1 - Company Overview

Scienture Logo

Scienture

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of pharmaceutical research focused on drug screening, with a pipeline including SCN-102 (oral cardiovascular liquid; FDA-accepted NDA), SCN-104 (self-injectable CNS/pain drug-device; advanced development), SCN-107 (long-acting pain injection; formulation optimization with pre-clinical planned), and SCN-106 (early-stage biosimilar; clone selection completed; BIA meeting planned).

Products and services

  • SCN-104: Drug-device combination for CNS/Pain enabling convenient self-injection, integrating medication with delivery mechanism for patient self-use (advanced-stage)
  • SCN-102: Oral liquid for cardiovascular use with an FDA-accepted NDA, in late-stage development, formulated for oral administration (NDA-accepted)
  • SCN-107: Injection product indicated for pain, currently in formulation optimization stage with pre-clinical studies planned (long-acting)

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Scienture

Neumora Logo

Neumora

HQ: United States Website
  • Description: Provider of clinical-stage investigational therapies for brain diseases, conducting trials to evaluate new treatments. Portfolio includes navacaprant, an investigational oral Phase 3 medication for major depressive disorder that modulates dopamine and reward processing pathways, plus NMRA-NLRP3 and NMRA-GCASE programs for neurodegenerative diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Neumora company profile →
Synchron Logo

Synchron

HQ: United States Website
  • Description: Provider of neuromodulation solutions in bioelectronics medicine for previously-untreatable nervous system conditions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Synchron company profile →
Sage Therapeutics Logo

Sage Therapeutics

HQ: United States Website
  • Description: Provider of novel medicines for central nervous system (CNS) disorders, focused on debilitating and disabling conditions. Offers ZURZUVAE, an oral 14-day treatment for adults with postpartum depression, and ZULRESSO, an injectable for patients 15+ with postpartum depression. Pipeline includes SAGE-689 (acute GABA hypofunction), SAGE-421 (NMDA hypofunction), and SAGE-319 (GABA hypofunction).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sage Therapeutics company profile →
Caraway Therapeutics Logo

Caraway Therapeutics

HQ: United States Website
  • Description: Provider of precision small-molecule therapeutics for CNS and rare diseases, developing medicines that enhance cellular clearance by activating the lysosome to remove toxic materials and defective cellular components. Leverages modulation of mitophagy and autophagy to use natural clearance pathways, preventing cell damage and treating neurodegenerative disease.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Caraway Therapeutics company profile →
NKGen Biotech Logo

NKGen Biotech

HQ: United States Website
  • Description: Provider of natural killer (NK) cell therapy candidates to restore immune function for cancer treatment, including SNK01, an autologous NK therapy in clinical trials for neurodegenerative diseases and various cancers, and SNK02, an allogeneic NK therapy being tested for solid tumors, plus an Expanded Access Program enabling access to investigational therapies under specific conditions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full NKGen Biotech company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Scienture

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Scienture

2.2 - Growth funds investing in similar companies to Scienture

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Scienture

4.2 - Public trading comparable groups for Scienture

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Scienture

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Scienture

What does Scienture do?

Scienture is a provider of pharmaceutical research focused on drug screening, with a pipeline including SCN-102 (oral cardiovascular liquid; FDA-accepted NDA), SCN-104 (self-injectable CNS/pain drug-device; advanced development), SCN-107 (long-acting pain injection; formulation optimization with pre-clinical planned), and SCN-106 (early-stage biosimilar; clone selection completed; BIA meeting planned).

Who are Scienture's competitors?

Scienture's competitors and similar companies include Neumora, Synchron, Sage Therapeutics, Caraway Therapeutics, and NKGen Biotech.

Where is Scienture headquartered?

Scienture is headquartered in United States.

How many employees does Scienture have?

Scienture has 1,000 employees 🔒.

When was Scienture founded?

Scienture was founded in 2010 🔒.

What sector and industry vertical is Scienture in?

Scienture is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Scienture

Who are the top strategic acquirers in Scienture's sector and industry

Top strategic M&A buyers and acquirers in Scienture's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Scienture?

Top strategic M&A buyers groups and sectors for Scienture include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Scienture's sector and industry vertical

Which are the top PE firms investing in Scienture's sector and industry vertical?

Top PE firms investing in Scienture's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Scienture's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Scienture's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Scienture's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Scienture include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Scienture's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Scienture?

The key public trading comparables and valuation benchmarks for Scienture include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Scienture for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Scienture with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Scienture's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Scienture with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Scienture's' sector and industry vertical?

Access recent funding rounds and capital raises in Scienture's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Scienture